A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1
AuthorKelleher, AD; Puls, RL; Bebbington, M; Boyle, D; Ffrench, R; Kent, SJ; Kippax, S; Purcell, DFJ; Thomson, S; Wand, H; ...
PublisherLIPPINCOTT WILLIAMS & WILKINS
AffiliationMicrobiology And Immunology
Document TypeJournal Article
CitationsKelleher, A. D., Puls, R. L., Bebbington, M., Boyle, D., Ffrench, R., Kent, S. J., Kippax, S., Purcell, D. F. J., Thomson, S., Wand, H., Cooper, D. A. & Emery, S. (2006). A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS, 20 (2), pp.294-297. https://doi.org/10.1097/01.aids.0000199819.40079.e9.
Access StatusThis item is currently not available from this repository
C1 - Journal Articles Refereed
An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 x 10(7) pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
KeywordsMedical Virology ; Infectious Diseases
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References